Phaseline

Companies › Mabwell (Shanghai) Bioscience

Mabwell (Shanghai) Bioscience: clinical trials, targets and expected readouts

13 active drug programs in 37 registered trials: 19 Phase 2, 14 Phase 1, 4 Phase 3; Oncology, Genitourinary, Other, Hematology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
9MW2821
nectin-4 antibody-drug conjugate with MMAE payload
NECTIN4Phase 3Advanced Urothelial Carcinoma; Urothelial Carcinoma; Cervical Cancer; Triple-Negative Breast CancerDec 2026
Toripalimab (JS001)
Programmed cell death protein 1 antagonist
PDCD1Phase 3Urothelial Carcinoma; Advanced Urothelial CarcinomaDec 2026
9MW3811
anti-IL-11 monoclonal antibody
IL11Phase 2ScarDec 2026
PD-1 inhibitor
PD-1 inhibitor
PDCD1Phase 2Triple-Negative Breast CancerJul 2027
9MW1911–Phase 2Chronic Obstructive Pulmonary Disease COPD; Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)Dec 2027
9MW2921–Phase 1Advanced Solid TumorDec 2026
bulumtatug fuvedotin
anti-TROP2 antibody-drug conjugate
TROP2Phase 1Triple Negative Breast CancerMay 2027
7MW4911–Phase 1GI Cancers; Solid TumorsJul 2027
7MW3711–Phase 1Solid TumorDec 2027
JS207–Phase 1Solid Tumor; Advanced Colorectal Cancer; NSCLC; Advanced Malignant Solid Tumors …Dec 2027
6MW5311
bispecific T cell engager antibody with bivalent binding to LILRB4 on tumor cells and mono
LILRB4, CD3EPhase 1AMLDec 2029
9MW3011–Phase 1Polycythemia Vera; Beta-Thalassemia–
9MW4113 injection
IL-4 receptor antagonist monoclonal antibody
–Phase 1Healthy Participants–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT067527469MW3011Phase 1Polycythemia VeraOncologyAug 2025
NCT061753519MW1911Phase 1Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)RespiratorySep 2025
NCT077913429MW4113 injectionPhase 1Healthy ParticipantsOtherJul 2026
NCT067727669MW3011Phase 1Beta-ThalassemiaHematologyOct 2026
NCT06885385JS207Phase 2Advanced Colorectal CancerOncologyNov 2026
NCT075766089MW3811Phase 2ScarOtherDec 2026
NCT06022250JS207Phase 1Advanced Malignant TumorOncologyDec 2026
NCT059904529MW2921Phase 1Advanced Solid TumorOncologyDec 2026
NCT060791129MW2821Phase 1Advanced Urothelial CarcinomaOncologyDec 2026
NCT06079112Toripalimab (JS001)Phase 1Advanced Urothelial CarcinomaOncologyDec 2026
NCT06944470JS207Phase 2NSCLCOncologyApr 2027
NCT06908928bulumtatug fuvedotinPhase 1Triple Negative Breast CancerOncologyMay 2027
NCT068234279MW2821Phase 2Urothelial CarcinomaGenitourinaryJun 2027
NCT06823427Toripalimab (JS001)Phase 2Urothelial CarcinomaGenitourinaryJun 2027
NCT061967369MW2821Phase 3Advanced Urothelial CarcinomaOncologyJul 2027
NCT064920059MW2821Phase 2Triple-Negative Breast CancerOncologyJul 2027
NCT06492005PD-1 inhibitorPhase 2Triple-Negative Breast CancerOncologyJul 2027
NCT072165607MW4911Phase 1GI CancersOncologyJul 2027
NCT072656227MW4911Phase 1Solid TumorsOncologyJul 2027
NCT065923269MW2821Phase 3Urothelial CarcinomaOncologySep 2027
NCT06592326Toripalimab (JS001)Phase 3Urothelial CarcinomaOncologySep 2027
NCT07480733JS207Phase 2Advanced Malignant Solid TumorsOncologyNov 2027
NCT07309276JS207Phase 2Advanced Lung CancerOncologyNov 2027
NCT066921669MW2821Phase 3Cervical CancerOncologyDec 2027
NCT072927149MW1911Phase 2Chronic Obstructive Pulmonary Disease COPDRespiratoryDec 2027
NCT07503756JS207Phase 2Metastatic Colorectal CancerOncologyDec 2027
NCT073147239MW2821Phase 2Urothelial CarcinomaOncologyDec 2027
NCT074661607MW3711Phase 1Solid TumorOncologyDec 2027
NCT07466160JS207Phase 1Solid TumorOncologyDec 2027
NCT06969027JS207Phase 2Non-small Cell Lung CancerOncologyDec 2027
NCT06954467JS207Phase 2Hepatocellular CarcinomaOncologyDec 2027
NCT07690787JS207Phase 2Recurrent/ Metastatic NPCOncologyDec 2027
NCT07314723Toripalimab (JS001)Phase 2Urothelial CarcinomaOncologyDec 2027
NCT07045311JS207Phase 2Triple-negative Breast CancerOncologyMar 2028
NCT07045311JS207Phase 2Triple-negative Breast CancerOncologyMar 2028
NCT06868836JS207Phase 2Non-squamous Non-small Cell Lung CancerOncologyApr 2028
NCT079145566MW5311Phase 1AMLOncologyDec 2029

Targets

PDCD1 (2) NECTIN4 (1) LILRB4 (1) CD3E (1) IL11 (1) TROP2 (1)

Companies with the same targets

Akeso Johnson & Johnson (Janssen) Regeneron Pharmaceuticals AstraZeneca Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech GSK Bio-Thera Solutions Shenyang Sunshine Pharmaceutical

Companies built like this

Bio-Thera Solutions Akeso Sichuan Baili Pharmaceutical Shenyang Sunshine Pharmaceutical Jiangsu Simcere Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.